NCT00940758View on ClinicalTrials.gov

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2014

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

PEP02

Dose escalation: 50-100 mg/m2 biweekly

Trial Locations (1)

704

National Cheng Kung University Hospital, Tainan City

Sponsors

Lead Sponsor

PharmaEngine
All Listed Sponsors
lead

PharmaEngine

INDUSTRY

NCT00940758 - Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy | Biotech Hunter | Biotech Hunter